METHOD FOR PREDICTION OF SURVIVAL OF PATIENTS WITH UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA Russian patent published in 2025 - IPC G01N33/68 G01N33/574 A61B6/03 A61B8/13 G16H50/30 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and may be used for the prediction of a survival rate in the patients with unresectable intrahepatic cholangiocarcinoma. Patient’s blood is sampled before and after chemotherapeutic treatment, patient’s blood is examined for the following tumour markers: cancer-embryonic antigen (CEA), ng/ml, and carbohydrate antigen 19-9 (CA 19-9), IU/ml, comparing the obtained values. Post-treatment CEA level is compared to the pre-therapeutic CEA level, and post-treatment CA 19-9 level is compared to pre-therapeutic CA 19-9 level. Derived values are scored: CEA level within reference values is estimated as complete response to treatment – 1 point; CA 19-9 level within reference values is estimated as a complete response to treatment – 1 point; reduction of the CEA level after treatment by 30 % or more relative to the pre-treatment level is considered to be a partial response – 2 points; decrease in post-therapeutic CA 19-9 level by 30% or more relative to the pre-therapeutic level is considered to be a partial response – 2 points; reducing the CEA level by less than 30% or increasing by no more than 20% relative to their pre-treatment level is considered to be stabilization – 3 points; reducing CA 19-9 level by less than 30% or increasing by no more than 20% relative to their pre-treatment level is considered to be stabilization – 3 points; increase in the CEA level by 20% or more relative to the pre-treatment level is considered to be a progression to this treatment – 4 points; increasing CA 19-9 level by 20% or more relative to the pre-therapeutic level is considered to be a progression to the given therapy – 4 points. In addition to the patient visualization and determination of the sizes of the tumour centres in bodies of a thorax and an abdominal cavity by means of CT or MRI prior to the beginning of chemotherapeutic treatment and after are carried out. Obtained data after treatment are compared with data before treatment. Obtained indicators are assigned points: the disappearance of tumour centres after treatment is estimated as a complete response to treatment – 1 point; reducing the size of tumour foci by 30% or more after treatment relative to their pre-treatment size is considered to be a partial response to treatment – 2 points; reducing the size of tumour foci by less than 30% and/or increasing the size by less than 20% relative to their pre-treatment sizes is considered to be stabilization – 3 points, increase in the size of tumour foci by 20% or more after the treatment relative to their size before the treatment and/or the appearance of one or more new foci is considered to be progression – 4 points. Points are summed up for each value. Point significance coefficient (K) is calculated by formula K = (x×1) + (y×2) + (z×3), where x is the number of points calculated for the CEA; y is the number of points calculated for CA 19-9; z is the number of points calculated for CT or MRI; 1 – CEA significance factors; 2 – CA 19-9 significance coefficients; 3 – the CT or MRI significance factors. If K falls within range of 6 to 18, a survival rate of more than 12 months is predicted. If K falls within range of 19 to 24, a survival rate of less than 12 months is predicted.

EFFECT: method enables predicting the survival rate in the patients with unresectable intrahepatic cholangiocarcinoma by measuring patient’s blood before and after the tumour markers CEA and CA 19-9 and comparing the derived values.

1 cl, 2 tbl, 4 ex